Open AccessSRC‐3/AIB1: transcriptional coactivator in oncogenesis 1
Author(s) -
YAN Jun,
TSAI Sophia Y,
TSAI Mingjer
Publication year - 2006
Publication title -
acta pharmacologica sinica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.514
H-Index - 90
eISSN - 1745-7254
pISSN - 1671-4083
DOI - 10.1111/j.1745-7254.2006.00315.x
Subject(s) - nuclear receptor coactivator 3 , coactivator , oncogene , proto oncogene tyrosine protein kinase src , cancer research , prostate cancer , cancer , biology , hormone , breast cancer , prostate carcinoma , receptor , endocrinology , medicine , bioinformatics , genetics , transcription factor , gene , cell cycle
Steroid receptor coactivator‐3 (SRC‐3, also known as NCoA3, AIB1, p/CIP, RAC3, ACTR, and TRAM1), localized on a frequently amplified region, 20q12, has been associated with multiple cancers, including breast, gastric and prostate cancers. Although SRC‐3 has been implicated as an oncogene, compelling evidence has only recently emerged implicating it as a causal factor in the genesis of human cancers. Here, we summarize recent evidence that indicates aberrant SRC‐3 expression is important in hormone‐sensitive and ‐insensitive human cancers.